[Examination of plasminogen-activators and plasmin-inhibitors in maternal and fetal rat-lung-tissue after administration of DL-carnitine-hydrochloride (author's transl)].
In the formation and resolution of fibrinous pulmonary hyaline membranes of the type occurring in perinatal respiratory distress, the plasminogen activators and plasmin inhibitors contained in the tissue assume central importance. Carnitine does not change plasminogen activator activity and reduces the plasmin inhibitor content in the foetal rat lung. Hence, no inhibiting action on local fibrinolytic processes can be established for carnitine.
D000818:Animals; D002331:Carnitine / Q000494:pharmacology*; D005260:Female; D005323:Fetal Monitoring; D006801:Humans; D006819:Hyaline Membrane Disease / Q000097:blood; D007231:Infant, Newborn; D008168:Lung / Q000032:analysis* / Q000187:drug effects / Q000196:embryology; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D010960:Plasminogen Activators / Q000032:analysis*; D011247:Pregnancy; D051381:Rats
D010960:Plasminogen Activators; D002331:Carnitine
Untersuchungen gewebeständiger Plasminogenaktivatoren und Plasmininihitoren maternaler und fetaler Rattenlungen nach Gave von DL-Carnitinhydrochlorid.